Syncom Formulation (India) (NSE:SYNCOMF) EV-to-EBIT : 32.07 (As of May. 11, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Syncom Formulation (India)'s Enterprise Value is ₹12,454 Mil. Syncom Formulation (India)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹388 Mil. Therefore, Syncom Formulation (India)'s EV-to-EBIT for today is 32.07.

The historical rank and industry rank for Syncom Formulation (India)'s EV-to-EBIT or its related term are showing as below:

NSE:SYNCOMF' s EV-to-EBIT Range Over the Past 10 Years
Min: 2.88 Med: 14.51 Max: 61.56
Current: 32.06

During the past 13 years, the highest EV-to-EBIT of Syncom Formulation (India) was 61.56. The lowest was 2.88. And the median was 14.51.

NSE:SYNCOMF's EV-to-EBIT is ranked worse than
74.14% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.95 vs NSE:SYNCOMF: 32.06

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Syncom Formulation (India)'s Enterprise Value for the quarter that ended in Dec. 2023 was ₹14,147 Mil. Syncom Formulation (India)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹388 Mil. Syncom Formulation (India)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.75%.

Syncom Formulation (India) EV-to-EBIT Historical Data

The historical data trend for Syncom Formulation (India)'s EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncom Formulation (India) EV-to-EBIT Chart

Syncom Formulation (India) Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBIT

Get a 7-Day Free Trial

6.61

2.80

5.70

33.36

19.05

Syncom Formulation (India) Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															33.15	19.05	22.60	23.02	36.40

Competitive Comparison of Syncom Formulation (India)'s EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syncom Formulation (India)'s EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s EV-to-EBIT falls into.

Syncom Formulation (India) EV-to-EBIT Calculation

Syncom Formulation (India)'s EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	12454.009	/	388.37
	=	32.07

Syncom Formulation (India)'s current Enterprise Value is ₹12,454 Mil.
Syncom Formulation (India)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹388 Mil.

Syncom Formulation (India) (NSE:SYNCOMF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Syncom Formulation (India)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	388.37	/	14147
	=	2.75 %

Syncom Formulation (India)'s Enterprise Value for the quarter that ended in Dec. 2023 was ₹14,147 Mil.
Syncom Formulation (India)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹388 Mil.

Syncom Formulation (India) EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » EV-to-EBIT

Traded in Other Exchanges

524470:India

Address

207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018

Website

https://www.sfil.in

Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines